A s a general rule patients who have diffuse large B-cell lymphoma who relapse after initial treatment will be offered an autologous stem cell transplant as the preferred treatment. However not every patient is able, or willing to undergo a stem cell transplant.
There is no single treatment alternative to SCT that is universally accepted as the "best" option for everyone. Therefore on this page we will try to give you a list of treatment options that are being used for relapsed DLBC, and other aggressive forms of NHL. Please be sure to discuss them with your doctor if you find yourself in this situation.
Phase II Trial Shows Zevalin(R) Effective Therapy for Relapsed/Refractory Patients With Diffuse Large B-Cell Lymphoma
90Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkins Lymphoma
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy
Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma
Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkins Lymphoma: Evidence of Antitumor Activity from a Phase I Study
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma
Relapsed and Refractory Primary Mediastinal Diffuse Large B-Cell Lymphoma: Outcome with ICE-Based Treatment
Note: In the abstract below BBR2778 is generic name for Pixantrone Preliminary Phase II Study Results of BBR2778 in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin's Lymphoma
Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkins Lymphoma
I fosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma
Phase I/II Study of Bortezomib Alone and Bortezomib with Dose-Adjusted EPOCH Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma
Treatment Response to Single Agent Sphingosomal Vincristine in Patients with Relapsed and/or Refractory Diffuse Aggressive Non-Hodgkin’s Lymphoma